Avastin, Erbitux Costs Invite Price Controls, Former NCI Deputy Says
Executive Summary
The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15
You may also be interested in...
Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication
FDA's full approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib) covers both refractory and first-line use
Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication
FDA's full approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib) covers both refractory and first-line use
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer